October 19, 2016 / 11:11 AM / a year ago

Federal Circuit rejects GSK patent on oral flu drug

A divided appeals court on Tuesday rejected British drugmaker GlaxoSmithKline’s attempts to revive a patent application for its orally-inhaled influenza drug, Relenza.

The 2-1 panel of the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the Patent Trial and Appeal Board (PTAB), which last year rejected a patent application filed by inventor Constantin Efthymiopoulos of Biota Pharmaceuticals, a Georgia-based firm that licenses to GSK the right to market Relenza.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2dqd7Fu

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below